FI90869B - Förfarande för framställning av såsom läkemedel användbara imidazoldinonderivat - Google Patents
Förfarande för framställning av såsom läkemedel användbara imidazoldinonderivat Download PDFInfo
- Publication number
- FI90869B FI90869B FI874865A FI874865A FI90869B FI 90869 B FI90869 B FI 90869B FI 874865 A FI874865 A FI 874865A FI 874865 A FI874865 A FI 874865A FI 90869 B FI90869 B FI 90869B
- Authority
- FI
- Finland
- Prior art keywords
- compound
- isopropanol
- group
- imidazolidinone
- solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (2)
1. Menetelmä lääkeaineena käyttökelpoisten imidatsoli-dinonijohdannaisten tai niiden farmaseuttisesti sopivien suolojen valmistamiseksi, joilla on yleinen kaava (I): 0 R-Q-N_N- (CH2) m" (*> n \^y (I) jossa R on pyridyyli- tai pyrimidinyyliryhmä; rengas A on fe-nyyli tai mono- tai disubstituoitu fenyyli, jolloin substi-tuentti(tit) on valittu ryhmästä halogeeniatomi, C1-C4-alkyy-li, Ci-Ci-alkoksi ja trihalogeeni-C1-C4-alkyyli; Y on viny-leeni- tai etynyleeniryhmä; m on kokoluku 1-6; n on kokoluku 0-2; ja Q on metyleeniryhmä tai yksinkertainen sidos, tunnettu siitä, että (a) kondensoidaan yleisen kaavan (II) mukainen yhdiste: xMc^-mn-^ (1) jossa Y, m, n ja rengas A merkitsevät samaa kuin edellä ja X1 esittää reaktiivista jäännöstä, joka on valittu ryhmästä; halogeeniatomi, fenyylisulfonyylioksiryhmä, alempi alkyyli-fenyylisulfonyylioksiryhmä, ja alempi alkyylisulfonyylioksi-ryhmä; yleisen kaavan (III) mukaisen yhdisteen, tai sen suolan kanssa: O A R-Q-N NH (III) 1_I jossa R ja Q merkitsevät samaa kuin edellä, tai (b) annetaan yleisen kaavan (IV) mukaisen yhdisteen, tai sen 90869 45 suolan: R-Q-NHCH2CH2NH- (CH2) m- (Y) (IV) jossa substituenteilla on samat merkitykset kuin edellä, reagoida karbonyloivan aineen kanssa, joka on valittu ryhmästä; karbonyylidi-imidatsoli, di-alempi-alkyylikarbonaatti, fos-geeni ja disukkini-imidikarbonaatti, tai (c) annetaan yleisen kaavan (V) mukaisen yhdisteen tai sen suolan: A R-Q-N_N- (CH2) τη- (Y) A J (V) jossa substituentit merkitsevät samaa kuin edellä, reagoida hapettavan aineen kanssa, joka on valittu ryhmästä; typpiha-poke ja dimetyylisulfoksidi-trifluorietikkahappo, tai (d) kondensoidaan yleisen kaavan (VI) mukainen yhdiste tai sen suola: R-Q-NHCONH- (CH2) m- (Y) (VI) jossa substituentit merkitsevät samaa kuin yllä, yleisen kaavan (VII) mukaisen yhdisteen kanssa: X2CH2CH2X3 (VII) jossa X2 ja X3 esittävät reaktiivista jäännöstä, joka on valittu ryhmästä; halogeeniatomi, fenyylisulfonyylioksiryhmä, alempi alkyylifenyylisulfonyylioksiryhmä ja alempi alkyyli-sulfonyylioksiryhmä, ja (e) tarvittaessa muutetaan näin saatu tuote farmaseuttisesti sopivaksi suolakseen. 46
1. Förfarande för framställning av säsom läkemedel använd-bara imidazoldinonderivat eller farmaceutiskt acceptabla salter därav enligt följande allmänna forrael (I): 0 R-Q-N_N-(CH2)m-(Y)n“^A^ (I) i vilken R är en pyridyl- eller en pyrimidinylgrupp; ringen A är en fenylgrupp eller en mono- eller disubstituerad fenyl-grupp, varvid substituenterna är valda ur gruppen; en halo-genatom, en C1-C4-alkyl/ en C1-C4-alkoxi och en trihalogen-C1-C4-alkyl; Y är en vinylen- eller etynylengrupp; m ett hel-tal 1-6; n är ett heltal 0-2; och Q är en metylengrupp eller en enkelbindning, k ännetecknat av, att man (a) kondenserar en förening enligt den allmänna formeln (II): Xl-(CH2,.-(Y)n^0 (II) i vilken Y, m, n och ringen A betecknar detsamma som ovan och X1 betecknar en reaktiv rest vald ur gruppen; en halogenatom, en fenylsulfonyloxigrupp, en lägre alkylfenylsulfonyloxigrupp och en lägre alkylsulfonyloxigrupp; med en förening enligt den allmänna formeln (III), eller dess sait: 0 ίΙΙΙΐ R-Q-N NH ' ' I_I li vilken R och Q betecknar detsamma som ovan, eller (b) läter en förening enligt den allmänna formeln (IV) eller 90869 47 dess salt: R-Q-NHCH2CH2NH- (CH2) m" (γ) n^) (IV) i vilken substituenterna betecknar detsamma som ovan, reagera med ett karbonylerande ämne vald ur gruppen; karbonyldi-imi-dazol, di-lägre alkylkarbonat, fosgen och disuccinimidkarbo-nat, eller (c) läter en förening enligt den allmänna formeln (V) eller dess salt: S R-Q-N N-(CH2)rn-(Y)n-^ (V> i vilken substituenterna betecknar detsamma som ovan, reagera med ett oxiderande ämne vald ur gruppen; salpetersyrlighet och dimetylsulfoxid-trifluorättiksyra, eller (d) kondenserar en förening enligt den allmänna formeln (VI) eller dess salt: R-Q-NHCONH-(CH2)m-(Y) <VI) i vilken substituenterna betecknar detsamma som ovan, med en förening enligt den allmänna formeln (VII) eller dess salt: X2CH2CH2X3 (VII) i vilken X2 och X3 betecknar en reaktiv rest vald ur gruppen en halogenatom, en fenylsulfonyloxigrupp, en lägre alkylfe-nylsulfonyloxigrupp och en lägre alkylsulfonyloxigrupp, och (e) omvandlar vid behov den sälunda erhällna produkten till sitt farmaceutiskt acceptabla salt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27265586 | 1986-11-14 | ||
| JP27265586 | 1986-11-14 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI874865A0 FI874865A0 (sv) | 1987-11-04 |
| FI874865A FI874865A (sv) | 1988-05-15 |
| FI90869B true FI90869B (sv) | 1993-12-31 |
| FI90869C FI90869C (sv) | 1994-04-11 |
Family
ID=17516947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI874865A FI90869C (sv) | 1986-11-14 | 1987-11-04 | Förfarande för framställning av såsom läkemedel användbara imidazoldinonderivat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4886817A (sv) |
| EP (1) | EP0268229B1 (sv) |
| JP (1) | JPS63239281A (sv) |
| KR (1) | KR930002488B1 (sv) |
| CN (1) | CN1017245B (sv) |
| AT (1) | ATE78033T1 (sv) |
| AU (1) | AU597444B2 (sv) |
| CA (1) | CA1304376C (sv) |
| DE (1) | DE3780259T2 (sv) |
| DK (1) | DK597687A (sv) |
| ES (1) | ES2046193T3 (sv) |
| FI (1) | FI90869C (sv) |
| GR (1) | GR3005227T3 (sv) |
| HU (1) | HU198199B (sv) |
| IE (1) | IE61446B1 (sv) |
| IL (1) | IL84409A (sv) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600430A (en) * | 1985-02-22 | 1986-07-15 | Eli Lilly And Company | Pyridinylimidazolidinone compounds |
| GB9224144D0 (en) * | 1992-11-18 | 1993-01-06 | Erba Carlo Spa | Phenyl-imidazolidinone derivatives and process for their preparation |
| JP3916092B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
| US7129359B2 (en) | 2002-07-09 | 2006-10-31 | National Health Research Institutes | Imidazolidinone compounds |
| JP2009513539A (ja) * | 2003-07-11 | 2009-04-02 | ベーリンガー・インゲルハイム・フエトメデイカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | ベンゾジアゼピンレセプターのアルファ３サブユニットに対する選択性を有する化合物を用いて中枢神経系障害を治療または予防する方法 |
| WO2005082054A2 (en) * | 2004-02-26 | 2005-09-09 | Sosei Co., Ltd. | Combinations for the treatment of fungal infections |
| US7259174B2 (en) * | 2004-05-25 | 2007-08-21 | National Health Research Institutes | Imidazolidinone compounds |
| US20080070867A1 (en) * | 2005-01-19 | 2008-03-20 | Metabasis Therapeutics, Inc. | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases |
| US8354434B2 (en) | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
| KR20130036080A (ko) | 2006-08-15 | 2013-04-09 | 제논 파마슈티칼스 인크. | 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물 |
| AU2013206248B2 (en) * | 2008-06-27 | 2016-06-23 | Xenon Pharmaceuticals Inc. | Organic compounds |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN102840229B (zh) * | 2012-08-31 | 2015-11-18 | 中国舰船研究设计中心 | 可调心螺旋桨轴承装置 |
| UA116023C2 (uk) * | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| UA118035C2 (uk) * | 2013-10-07 | 2018-11-12 | Сінгента Партісіпейшнс Аг | Гербіцидні сполуки |
| UA120309C2 (uk) | 2015-06-03 | 2019-11-11 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ184081A (en) * | 1976-06-01 | 1980-10-08 | Velsicol Chemical Corp | 1-thiazol-2-yl-1 3-imidazolidn-2-ones |
| US4604127A (en) * | 1984-07-17 | 1986-08-05 | Eli Lilly And Company | Herbicidal pyridazinylimidazolidinone compounds |
| JPS6133172A (ja) * | 1984-07-24 | 1986-02-17 | Kotobuki Seiyaku Kk | １，３−置換−２−イミダゾリジノン誘導体，胃腸運動亢進剤及びその製造方法 |
| AU568789B2 (en) * | 1985-02-22 | 1988-01-07 | Mitsui Toatsu Chemicals Inc. | 3,3'-dinitrodiphenylether from m-dinitrobenzene |
| US4600430A (en) * | 1985-02-22 | 1986-07-15 | Eli Lilly And Company | Pyridinylimidazolidinone compounds |
| JPH06133172A (ja) * | 1992-10-20 | 1994-05-13 | Fujitsu General Ltd | ファクシミリ装置 |
-
1987
- 1987-11-04 FI FI874865A patent/FI90869C/sv not_active IP Right Cessation
- 1987-11-05 JP JP62280203A patent/JPS63239281A/ja active Granted
- 1987-11-09 IL IL84409A patent/IL84409A/xx not_active IP Right Cessation
- 1987-11-12 AU AU81125/87A patent/AU597444B2/en not_active Ceased
- 1987-11-13 HU HU875064A patent/HU198199B/hu not_active IP Right Cessation
- 1987-11-13 KR KR1019870012808A patent/KR930002488B1/ko not_active IP Right Cessation
- 1987-11-13 DK DK597687A patent/DK597687A/da not_active Application Discontinuation
- 1987-11-13 EP EP87116792A patent/EP0268229B1/en not_active Expired - Lifetime
- 1987-11-13 ES ES198787116792T patent/ES2046193T3/es not_active Expired - Lifetime
- 1987-11-13 CA CA000551760A patent/CA1304376C/en not_active Expired - Fee Related
- 1987-11-13 CN CN87107864A patent/CN1017245B/zh not_active Expired
- 1987-11-13 AT AT87116792T patent/ATE78033T1/de not_active IP Right Cessation
- 1987-11-13 DE DE8787116792T patent/DE3780259T2/de not_active Expired - Lifetime
- 1987-11-13 IE IE306387A patent/IE61446B1/en not_active IP Right Cessation
-
1988
- 1988-12-29 US US07/292,211 patent/US4886817A/en not_active Expired - Fee Related
-
1992
- 1992-07-17 GR GR920401559T patent/GR3005227T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI874865A0 (sv) | 1987-11-04 |
| IL84409A (en) | 1991-12-15 |
| FI90869C (sv) | 1994-04-11 |
| US4886817A (en) | 1989-12-12 |
| EP0268229A2 (en) | 1988-05-25 |
| KR930002488B1 (ko) | 1993-04-02 |
| JPH05396B2 (sv) | 1993-01-05 |
| DK597687A (da) | 1988-05-15 |
| AU597444B2 (en) | 1990-05-31 |
| ATE78033T1 (de) | 1992-07-15 |
| FI874865A (sv) | 1988-05-15 |
| IE873063L (en) | 1988-05-14 |
| IL84409A0 (en) | 1988-04-29 |
| CN1017245B (zh) | 1992-07-01 |
| DE3780259D1 (de) | 1992-08-13 |
| KR880006231A (ko) | 1988-07-22 |
| DE3780259T2 (de) | 1992-12-24 |
| AU8112587A (en) | 1988-05-19 |
| HUT45983A (en) | 1988-09-28 |
| ES2046193T3 (es) | 1994-02-01 |
| JPS63239281A (ja) | 1988-10-05 |
| CA1304376C (en) | 1992-06-30 |
| EP0268229A3 (en) | 1990-09-19 |
| GR3005227T3 (sv) | 1993-05-24 |
| DK597687D0 (da) | 1987-11-13 |
| EP0268229B1 (en) | 1992-07-08 |
| HU198199B (en) | 1989-08-28 |
| IE61446B1 (en) | 1994-11-02 |
| CN87107864A (zh) | 1988-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI90869B (sv) | Förfarande för framställning av såsom läkemedel användbara imidazoldinonderivat | |
| US4563455A (en) | Antiulcer fused imidazole compounds | |
| JP3155009B2 (ja) | イミダゾール誘導体 | |
| US6495582B1 (en) | Isoxazole compositions useful as inhibitors of ERK | |
| KR100442561B1 (ko) | ５산화２질소신타아제의억제제로유용한환상아미디노제 | |
| FI81096C (sv) | Förfarande för framställning av terapeutiskt användbara 2-(N-substitue rad guanidino)-4-heteroaryltiazolföreningar | |
| EP0784612A1 (en) | Urea derivatives and their use as acat-inhibitors | |
| CZ18194A3 (en) | Five-membered heterocycles, processes of their preparations and medicaments in which they are comprised | |
| WO2005066151A2 (en) | Histone deacetylase inhibitors | |
| WO2007061360A2 (en) | Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides | |
| US6649643B1 (en) | Imidazol-4-ylmehanols and their use as inhibitors of steroid C17-20 lyase | |
| JP7446316B2 (ja) | 置換ピロリジンアミドｉｉｉ | |
| WO1994026738A1 (en) | N'-heterocyclyl-n-benzofuranyl urea derivatives and their analogs as acat inhibitors | |
| BRPI0719002A2 (pt) | Compostos de pirazol e triazol substituídos como inibidores de ksp | |
| JP3218045B2 (ja) | 新規なチオフェン誘導体及びその医薬組成物 | |
| JP4757382B2 (ja) | 神経保護作用を有するトリアゾロン | |
| HUT73526A (en) | Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same | |
| EP4212524A1 (en) | Cd73 inhibitor and application thereof in medicine | |
| EP0413343B1 (en) | Furan derivatives | |
| US4968683A (en) | 6-oxo-pyridazine derivatives, a process for their preparation and medicaments containing these compounds | |
| US4550118A (en) | Heterocyclic compounds | |
| JPH08337579A (ja) | グアニジノチアゾ−ルおよびその抗潰瘍剤、ｈ２−受容体拮抗剤および抗菌剤としての用途 | |
| EP1261589A1 (en) | Imidazole compounds and their use as adenosine deaminase inhibitors | |
| JPH0577652B2 (sv) | ||
| US20040236114A1 (en) | Imidazole derivatives as adenosine deaminase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: TANABE SEIYAKU CO., . LTD. |